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Charlson Comorbidities IndexSummaryDescription: The Charlson Comorbidity Index (CCI) was
developed and validated as a measure of 1-year mortality risk
and burden of disease.1–4 To account for age being an independent
predictor of mortality, a Combined Age-CCI (CA-CCI) score can be
generated.1–3 The CCI has been extensively used in clinical research
to address the confounding inﬂuence of comorbidities, predict
outcomes, standardise comorbidities abstracted from medical
records or administrative databases and for self report of
comorbidities.1,3,5–9 In clinical practice, the CCI reduces comorbid-
ities into a single numeric score thatmayassist health professionals
with stratifying patients into subgroups based on disease severity,
developing targeted models of care and resource allocation.3,8
The CCI consists of 17 comorbidities, with two subcategories for
diabetes and liver disease.1–3 Comorbidities are weighted from 1 to
6 formortality risk anddisease severity, and then summed to form the
total CCI score.1–3 The CA-CCI is generated by adding 1 point to the CCI
score for each decade of age over 40 years.1–3 The CCI and CA-CCI
require minimal training and are freely available for researchers and
health professionals, with guidelines reported in Charlson et al.1 To
enable rapid electronic calculation of the CCI and CA-CCI, a Microsoft
excel spreadsheet has been developed.3 The CCI has been modiﬁed,
withadaptationstocomorbidities,administrationandscoring.3–7,9The
Self Reported-CCI (SR-CCI) can be self-administered or performed as a
10-minute interview.6,7 The SR-CCI uses the same scoring algorithm
as the CCI, except presence of liver disease is scored as 2 points.6,7
Psychometricproperties:TheCCI is reliableandvalid fordiverse
clinical cohorts (eg, cancer, amputation and arthritis) in a variety of
healthcare settings.3,4,8,9 Charlson Comorbidity Index scores 
5havebeenassociatedwith a 1-yearmortalityof 85%,while 10-year
survival for a CA-CCI of 5 was 34%.1 Charlson Comorbidity Index
scores> 8 have not been well studied.1,3,10 Due to advances in
disease management, the CCI was updated using Internationalhttp://dx.doi.org/10.1016/j.jphys.2016.05.008
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Classiﬁcation of Diseases 10 codes and validated in six nations,
includingAustralia.4 TheupdatedCCI andoriginal CCI demonstrated
similar levels of discrimination for in-hospital mortality with C
statistics of 0.727 to 0.878 and 0.723 to 0.882, respectively.4
The CCI has moderate to good inter-rater reliability of 0.74 to
0.945 in older cohorts with cancer.3,9 The CCI and SR-CCI have high
test re-test reliability with intraclass correlation coefﬁcients of
0.92 (p < 0.0001) and 0.91 (p < 0.0001), respectively.7 A moderate
level of agreementwas identiﬁed between the SR-CCI and CCI, with
most items having Kappa statistics (K) ranging from 0.433 to 0.541
(p < 0.0001), while diabetes had a high level of agreement
(K = 0.764; p < 0.0001).6 Spearman correlations up to 0.63 have
been reported between the SR-CCI and CCI.6,7
The CCI has content validity, as the diseases and severity
weights were statistically derived from relative risks of a
proportional regression model to predict mortality.1,9–11 One
weakness that has been reported for the CCI is omission of diseases
(eg, anaemia, mental illness), which are present in other
indices.3,11,12 However, the updated CCI retained 12 comorbidities,
and prediction of mortality remained high. Increased number of
comorbidities in indices (ie, 30 in the Elixhauser Comorbidity
Measure versus 17 in the CCI) also potentially reduces utility.4,11
Traditional construct validity using the known groupsmethod is
rarely tested in comorbidity indices.10,11 Poorer utilisation of cancer
screening in patientswith high CCI scores is an example of construct
validity for the CCI.10,11 There is no gold standard measure for
comorbidity, so criterion validity (which encompasses concurrent
and predictive validity) has been demonstrated for the CCI through
comparison to other comorbidity indices and prediction of out-
comes.1,5,8–11 The CCI hasmoderate to good correlation (> 0.4) with
other comorbidity indices and predictive validity for criterion such
as mortality, readmission, disability and length of stay.3,7,9,11CommentaryComorbidity, which impacts on contemporary clinical practice and
research, is a major consideration in health systems reform and
funding models.8 However, there is a lack of consensus on the most
effective method for measuring comorbidity.3,8–12 To ensure imple-
mentation of a comorbidity index that is sensitive, it is important to
determine if theoutcomeof interest ismortalityor function.9,12TheCCI
has utility due to lowcost, ease of administration and interpretation in
efﬁcient timeframes.3,7–9 The CCI is feasible in various healthcare
settings, including those with limited access to medical records (eg,
primary care, outreach).9 The CCI can be incorporated into electronic
medical record and data collection systems.3 The SR-CCI has the
potential to be biased by the client’s medical knowledge, recall or
literacy.6,7,9 Depending on primary diagnosis and comorbidities
being investigated, the CCI score may differ between studies (eg, in
a clientwith leukaemia, COPDandmyocardial infarction, the CCI score
can be 2 or 3).3 To enable standardised comparison of healthcare
outcomes between different cohorts and centres, further research on
measurement of comorbidity is warranted.Provenance: Invited. Not peer reviewed.
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